CHARLES & COLVARD LTD: Nasdaq/NYSE listing notice — Charles & Colvard to be delisted from Nasdaq on April 25, 2025 for failure to file quarterly reports

CHARLES & COLVARD LTD

Received Nasdaq determination letter on April 16, 2025 for non-compliance with Listing Rule 5250(c)(1) due to unfiled Forms 10-Q.
Company will not appeal; trading suspension effective April 25, 2025, followed by Form 25-NSE delisting filing.
Common stock (CTHR) expected to quote on OTC Experts Market; no assurance of trading market or broker-dealer quotes.
Decision driven by cost savings; Company filed annual 10-K but missed quarterly filings.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

CHARLES & COLVARD LTD received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 16, 2025, the Company received a staff determination letter (the “Letter”) from the Listing Qualifications staff (the “Staff”), which states that, since the Company did not file the Forms 10-Q prior to the Extension Date, the Company is out of compliance with the Listing Rule. The Company does not intend to appeal the Staff’s determination. As a result, trading of the Company’s common stock will be suspended from The Nasdaq Capital Market at the opening of business on April 25, 2025, and a Form 25-NSE will be filed with the SEC, which will remove the Company’s securities from listing and

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-25-037514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.